BiotechTube

LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor

Trial Timeline

Oct 21, 2024 → Jan 1, 2030

NCT ID
NCT06607185

About LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab

LY4066434. + Cetuximab + Nab paclitaxel + Gemcitabine + Oxaliplatin + Leucovorin + Irinotecan + 5Fluorouracil + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab is a phase 1 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06607185. Target conditions include Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved

Approved (9) Terminated (4) Active (11)
✅DalteparinEisaiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PlaceboAbbVieApproved
✅Pancrelipase CapsulesAbbVieApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06607185Phase 1Active

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
pemetrexedEli LillyPhase 2
35
mFOLFIRINOX + RamucirumabEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
enzastaurin + gemcitabineEli LillyPhase 2
35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
29
RamucirumabEli LillyPhase 1/2
32
GEMZAR + ALIMTAEli LillyPhase 3
40
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
35
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
29
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
29
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
40